Cargando…
Preparing for the incoming wave of biosimilars in oncology
With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages e...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144900/ https://www.ncbi.nlm.nih.gov/pubmed/30245864 http://dx.doi.org/10.1136/esmoopen-2018-000420 |
_version_ | 1783356165720113152 |
---|---|
author | Wolff-Holz, Elena Garcia Burgos, Juan Giuliani, Rosa Befrits, Gustaf de Munter, Johan Avedano, Luisa Aitken, Murray Gonzalez-Quevedo, Rosa Vyas, Malvika de Vries, Elisabeth G E Tabernero, Josep |
author_facet | Wolff-Holz, Elena Garcia Burgos, Juan Giuliani, Rosa Befrits, Gustaf de Munter, Johan Avedano, Luisa Aitken, Murray Gonzalez-Quevedo, Rosa Vyas, Malvika de Vries, Elisabeth G E Tabernero, Josep |
author_sort | Wolff-Holz, Elena |
collection | PubMed |
description | With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology’s Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency. |
format | Online Article Text |
id | pubmed-6144900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-61449002018-09-21 Preparing for the incoming wave of biosimilars in oncology Wolff-Holz, Elena Garcia Burgos, Juan Giuliani, Rosa Befrits, Gustaf de Munter, Johan Avedano, Luisa Aitken, Murray Gonzalez-Quevedo, Rosa Vyas, Malvika de Vries, Elisabeth G E Tabernero, Josep ESMO Open Review With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology’s Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency. BMJ Publishing Group 2018-09-05 /pmc/articles/PMC6144900/ /pubmed/30245864 http://dx.doi.org/10.1136/esmoopen-2018-000420 Text en © Author (s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Review Wolff-Holz, Elena Garcia Burgos, Juan Giuliani, Rosa Befrits, Gustaf de Munter, Johan Avedano, Luisa Aitken, Murray Gonzalez-Quevedo, Rosa Vyas, Malvika de Vries, Elisabeth G E Tabernero, Josep Preparing for the incoming wave of biosimilars in oncology |
title | Preparing for the incoming wave of biosimilars in oncology |
title_full | Preparing for the incoming wave of biosimilars in oncology |
title_fullStr | Preparing for the incoming wave of biosimilars in oncology |
title_full_unstemmed | Preparing for the incoming wave of biosimilars in oncology |
title_short | Preparing for the incoming wave of biosimilars in oncology |
title_sort | preparing for the incoming wave of biosimilars in oncology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144900/ https://www.ncbi.nlm.nih.gov/pubmed/30245864 http://dx.doi.org/10.1136/esmoopen-2018-000420 |
work_keys_str_mv | AT wolffholzelena preparingfortheincomingwaveofbiosimilarsinoncology AT garciaburgosjuan preparingfortheincomingwaveofbiosimilarsinoncology AT giulianirosa preparingfortheincomingwaveofbiosimilarsinoncology AT befritsgustaf preparingfortheincomingwaveofbiosimilarsinoncology AT demunterjohan preparingfortheincomingwaveofbiosimilarsinoncology AT avedanoluisa preparingfortheincomingwaveofbiosimilarsinoncology AT aitkenmurray preparingfortheincomingwaveofbiosimilarsinoncology AT gonzalezquevedorosa preparingfortheincomingwaveofbiosimilarsinoncology AT vyasmalvika preparingfortheincomingwaveofbiosimilarsinoncology AT devrieselisabethge preparingfortheincomingwaveofbiosimilarsinoncology AT tabernerojosep preparingfortheincomingwaveofbiosimilarsinoncology |